Production (Stage)
Regen BioPharma, Inc.
RGBP
$0.07
$0.028970.32%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 59.10K | 59.40K | 59.10K | 59.10K | 59.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.10K | 59.40K | 59.10K | 59.10K | 59.10K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 59.10K | 59.40K | 59.10K | 59.10K | 59.10K |
| SG&A Expenses | 120.40K | 112.20K | 134.50K | 120.00K | 134.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.40K | 145.70K | 167.00K | 160.10K | 181.80K |
| Operating Income | -61.40K | -86.40K | -108.00K | -101.10K | -122.80K |
| Income Before Tax | -515.40K | -264.90K | -130.10K | -122.50K | -144.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -515.40K | -264.90K | -130.10K | -122.50K | -144.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -515.40K | -264.90K | -130.10K | -122.50K | -144.90K |
| EBIT | -61.40K | -86.40K | -108.00K | -101.10K | -122.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.13 | -0.03 | -0.01 | -0.02 | -0.04 |
| Normalized Basic EPS | -0.08 | -0.02 | -0.01 | -0.01 | -0.03 |
| EPS Diluted | -0.13 | -0.03 | -0.01 | -0.02 | -0.04 |
| Normalized Diluted EPS | -0.08 | -0.02 | -0.01 | -0.01 | -0.03 |
| Average Basic Shares Outstanding | 4.11M | 9.04M | 8.43M | 7.88M | 3.60M |
| Average Diluted Shares Outstanding | 4.11M | 9.04M | 8.43M | 7.88M | 3.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |